ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) ...
Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
Congenital lower urinary tract obstruction, often presenting as fetal megacystis, is defined in the first trimester by a longitudinal bladder diameter greater than 7 mm on ultrasonography. It most ...
LOS ANGELES, CA– In a groundbreaking achievement set to reshape the future of transplant medicine, Dr. Inderbir S. Gill has led the world’s first successful bladder transplant in a human being. The ...
Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning ...
Sacituzumab Govitecan Plus Pembrolizumab Shows Promise for Bladder Sparing in Muscle-Invasive Cancer
Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...
Liquid biopsy guided disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer (DECIDING-I study). This is an ASCO Meeting ...
When Keeley Hellberg first showed symptoms of a urinary tract infection (UTI) in late 2021, she went to her doctor for help. She thought it would clear up quickly, but even after four rounds of ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results